Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL614580 Target Snapshot

HT-1080 · CELL-LINE · Homo sapiens

3,024Compounds
994Assays
43Approved Drugs
2,767.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats HT-1080 as ChEMBL target CHEMBL614580. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
HT-1080
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL614580
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether HT-1080 still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelHT-1080
UniProt AccessionN/A

HT-1080

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as HT-1080.

Review nameHT-1080
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

43
Approved
13
Phase III
23
Phase II
5
Phase I
Assay Mix

Activity Type Distribution

IC501,940.0
EC50827.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5082180 10.1 IC50 0.08 Preclinical
CHEMBL553025 10.0 IC50 0.1 Approved
CHEMBL159 10.0 IC50 0.099 Approved
CHEMBL96926 9.95 IC50 0.112 Preclinical
CHEMBL56157 9.85 IC50 0.14 Preclinical
CHEMBL428647 9.82 IC50 0.15 Approved
CHEMBL5270787 9.52 IC50 0.3 Preclinical
CHEMBL90555 9.52 IC50 0.3 Approved
CHEMBL123626 9.51 IC50 0.31 Preclinical
CHEMBL65 9.4 IC50 0.3944 Preclinical
Distribution

pChEMBL Value Distribution

367
5.0
320
5.5
250
6.0
162
6.5
171
7.0
143
7.5
61
8.0
27
8.5
12
9.0
7
9.5
pChEMBL
Approved Drugs

Approved Drugs

IVOSIDENIB
CHEMBL3989958
Approved 2018
MIDOSTAURIN
CHEMBL608533
Approved 2017
BOSUTINIB
CHEMBL288441
Approved 2012
TEMSIROLIMUS
CHEMBL1201182
Approved 2007
VORINOSTAT
CHEMBL98
Approved 2006
TOPOTECAN
CHEMBL84
Approved 1996
GEMCITABINE
CHEMBL888
Approved 1996
DOCETAXEL
CHEMBL3545252
Approved 1995
DOCETAXEL ANHYDROUS
CHEMBL92
Approved 1995
VINORELBINE
CHEMBL553025
Approved 1994
PACLITAXEL
CHEMBL428647
Approved 1992
MITOXANTRONE
CHEMBL58
Approved 1987
ETOPOSIDE
CHEMBL44657
Approved 1983
MITOMYCIN
CHEMBL105
Approved 1981
DOXORUBICIN
CHEMBL53463
Approved 1974
DOXORUBICIN HYDROCHLORIDE
CHEMBL359744
Approved 1974
FLOXURIDINE
CHEMBL917
Approved 1970
CYTARABINE
CHEMBL803
Approved 1969
VINBLASTINE
CHEMBL159
Approved 1965
VINCRISTINE
CHEMBL90555
Approved 1963
COLCHICINE
CHEMBL107
Approved 1961
PROMETHAZINE
CHEMBL643
Approved 1951
Assay Landscape

Assay Landscape

995
Total Assays
1,685
Tested Compounds
3
Assay Types
Functional — 969 assays, 1,685 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 925 1,666 5.9
organism-based format 43 0
assay format 1 19 6.8
ADME — 22 assays, 15 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 22 15 5.6
Toxicity — 4 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 4 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine